On follow up study, elevated CA 125 in a case of epithelial ovarian tumour should be fuher evaluated with

CT Scan Evaluation of patients with suspected ovarian cancer should include measurement of serum levels of the tumour marker CA-125. CA-125 determinants are glycoproteins with molecular masses from 220 to 1000 kDa, and a radioimmunoassay is used to determine circulating CA-125 antigen levels. Between 80 and 85% of patients with epithelial ovarian cancer have levels of CA-125 _ 35 U/mL. Other malignant tumours can also elevate CA-125 levels, including cancers of the endometrium, cervix, fallopian tubes, pancreas, breast, lung, and colon. Ceain nonmalignant conditions that can produce moderate elevations of CA-125 levels include pregnancy, endometriosis, pelvic inflammatory disease, and uterine fibroids. About 1% of normal females have serum CA-125 levels _35 U/mL.